We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Eisai Company Ltd (PK) | USOTC:ESALY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 61.51 | 61.51 | 61.86 | 0.00 | 01:00:00 |
From Jun 2021 to Jun 2024
By Michael Dabaie
Biogen Inc. and Eisai Co. said the First Committee on New Drugs of Japan's Pharmaceutical Affairs and Food Sanitation Council decided to continue deliberations on the application for approval of aducanumab in Alzheimer's disease.
The council advises Japan's ministry of health, labor and welfare.
The NDC is seeking additional data to be submitted as part of this process. The companies said they will continue to engage with the Pharmaceuticals and Medical Devices Agency to agree on additional data requirements.
Biogen and Eisai said they remain committed to bringing aducanumab expeditiously to patients in Japan. The companies are collaborating on the global co-development and co-promotion of the medication.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 22, 2021 08:11 ET (13:11 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Eisai (PK) Chart |
1 Month Eisai (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
